Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

Exclusion Criteria

• •Subjects who experienced an ARQ-151 treatment-related AE or a serious AE (SAE) that precluded further treatment with ARQ-151 cream in a prior ARQ-151 cream study.
• •Planned excessive exposure of treated area(s) to either natural or artificial sunlight, tanning bed or other LED.
• •Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.
• •Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.
• •Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation of investigational product.
• •Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.